Nephrotoxicity Prevention and Management

High-Risk Nephrotoxic Drug Categories

• The American College of Cardiology recommends that NSAIDs, aminoglycosides, ACE inhibitors/ARBs, contrast media, calcineurin inhibitors, and chemotherapeutic agents be used with caution due to their potential to cause nephrotoxicity, with the "triple whammy" combination of NSAIDs + diuretics + ACE inhibitors/ARBs more than doubling acute kidney injury risk 1
• Aminoglycosides cause direct tubular toxicity and increase AKI odds by 53%, with risk compounding when combined with other nephrotoxins 1
• Vancomycin causes nephrotoxicity particularly at prolonged peak concentrations above 12 mcg/mL and trough levels above 2 mcg/mL 2
• All NSAIDs, including COX-2 inhibitors, cause renovasoconstriction and precipitate AKI, especially in patients with pre-existing kidney insufficiency or diminished kidney blood flow 1, 2
• ACE inhibitors and ARBs alter intraglomerular hemodynamics through efferent arteriole dilation, decreasing renal perfusion pressure 1, 2
• Calcineurin inhibitors cause direct nephrotoxicity 1, 4
• Cisplatin has preferential nephrotoxicity potential through direct tubular injury 4
• Tyrosine kinase inhibitors cause tubulointerstitial injury 4
• BRAF inhibitors cause tubulointerstitial injury and AKI 4
• Proteasome inhibitors may be associated with thrombotic microangiopathy 4
• Immune checkpoint inhibitors cause AKI primarily through acute interstitial nephritis and acute tubular injury 4
• Methotrexate causes crystalline nephropathy through tubular obstruction 4
• IV or intra-arterial contrast media cause nephrotoxicity especially in patients with pre-existing kidney dysfunction such as diabetic nephropathy 1, 2

Mechanisms of Nephrotoxicity

• NSAIDs cause afferent arteriole constriction reducing renal perfusion 1
• ACE inhibitors/ARBs cause efferent arteriole dilation decreasing glomerular filtration pressure 1
• Acute interstitial nephritis occurs through type IV delayed-type hypersensitivity response, commonly with antibiotics and immune checkpoint inhibitors 4
• Methotrexate causes intratubular crystal deposition and obstruction 4
• Anti-angiogenesis drugs and proteasome inhibitors cause endothelial dysfunction and TMA 4

High-Risk Drug Combinations

• The "triple whammy" combination of NSAIDs + diuretics + ACE inhibitors/ARBs more than doubles AKI risk, with 25% of non-critically ill patients developing AKI when receiving three or more nephrotoxins 1
• Macrolide antibiotics + statins increase AKI risk from rhabdomyolysis due to impaired statin clearance via CYP3A4 inhibition 1
• Escalating from two to three nephrotoxic medications more than doubles AKI risk 1

Risk Factors for Drug-Induced Nephrotoxicity

• Pre-existing chronic kidney disease significantly increases vulnerability 1
• Diabetes mellitus increases risk of drug-induced nephrotoxicity 1
• Previous history of AKI elevates risk 1
• Hypercalcemia increases nephrotoxicity risk 1

Prevention Strategies

• Administer potentially nephrotoxic medications only when needed and for the shortest duration possible 1
• Use less nephrotoxic alternatives: acetaminophen for non-inflammatory pain instead of NSAIDs 1
• Avoid NSAIDs entirely in patients with pre-existing kidney insufficiency or diminished kidney blood flow 1
• Monitor kidney function (serum creatinine, BUN, creatinine clearance) in all patients exposed to nephrotoxic agents 1
• Ensure adequate hydration, especially when administering contrast media or other high-risk agents 1
• Consider N-acetylcysteine before contrast studies in high-risk patients 1
• Educate patients to avoid over-the-counter NSAIDs during UTI episodes and other high-risk situations 3
• Instruct patients to consult before taking new medications, particularly decongestants, antivirals, antibiotics, and herbal products 1